| Recruiting | Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN281 NCT06980038 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, H NCT07484139 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Not Yet Recruiting | Artificial Intelligence for the Diagnosis of Oral Lesions NCT07529769 | Assistance Publique - Hôpitaux de Paris | — |
| Not Yet Recruiting | Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma NCT07335380 | NYU Langone Health | Phase 1 |
| Not Yet Recruiting | Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer NCT07058805 | Olgun Elicin | Phase 2 |
| Recruiting | Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Sq NCT07121595 | University of Michigan Rogel Cancer Center | Phase 2 |
| Recruiting | Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel NCT06947668 | University of Erlangen-Nürnberg Medical School | — |
| Recruiting | Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin a NCT06662058 | Emory University | N/A |
| Recruiting | Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy f NCT06532279 | NRG Oncology | Phase 2 |
| Terminated | A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade NCT05316688 | University of Washington | Phase 1 / Phase 2 |
| Withdrawn | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carbopl NCT06084845 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Recruiting | Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC) NCT06097468 | University of California, San Francisco | Phase 1 / Phase 2 |
| Withdrawn | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor NCT04892875 | Jennifer Choe | Phase 1 |
| Recruiting | Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 NCT05681039 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy fo NCT05749042 | Xin-Hua Xu | Phase 2 |
| Unknown | Articulatory Adaptation Following Oral Cancer Treatment NCT05876247 | University Medical Center Groningen | — |
| Unknown | Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell Carcinoma NCT05578170 | Nanfang Hospital, Southern Medical University | — |
| Recruiting | Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Orophary NCT05098119 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Completed | Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre Experience NCT05950737 | Tata Memorial Hospital | N/A |
| Recruiting | First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients NCT04858269 | Wake Forest University Health Sciences | Phase 2 |
| Terminated | Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Ca NCT04801472 | Institut de cancérologie Strasbourg Europe | N/A |
| Completed | Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC NCT04725396 | UNICANCER | N/A |
| Recruiting | Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Ca NCT04333537 | NRG Oncology | Phase 2 / Phase 3 |
| Terminated | Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Ne NCT04445064 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Phase 2 |
| Completed | IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma NCT03381183 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Unknown | Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction NCT03843515 | Amsterdam UMC, location VUmc | Phase 1 |
| Active Not Recruiting | Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck NCT03854032 | Thomas Jefferson University | Phase 2 |
| Completed | Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma NCT03618654 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | EARLY_Phase 1 |
| Completed | Biofeedback Rehabilitation to Improve Speaking and Eating in Public NCT03650699 | University Health Network, Toronto | N/A |
| Active Not Recruiting | Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cav NCT03784066 | Universitaire Ziekenhuizen KU Leuven | Phase 1 / Phase 2 |
| Completed | Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation NCT03510390 | Insel Gruppe AG, University Hospital Bern | N/A |
| Completed | Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer NCT02923258 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 2 / Phase 3 |
| Completed | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck NCT03258554 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Completed | WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer NCT03028766 | University of Birmingham | Phase 1 |
| Completed | Saliva-based Detection of CD44 NCT03148665 | Joseph Califano | — |
| Unknown | Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients NCT03529604 | University of Zagreb | — |
| Terminated | Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck NCT02582008 | Wake Forest University Health Sciences | EARLY_Phase 1 |
| Unknown | Radioguided Selective Neck Dissection for Staging and Treatment of Oral Cavity and Oropharyngeal Squamous Cell NCT03727594 | University Hospital of Ferrara | — |
| Terminated | Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral Can NCT03053960 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | — |
| Unknown | Feasibility of CTCs Isolation for Transcriptomes and Genome Wide Associated Analysis in Post-OP High Risk OSCC NCT03917524 | Chang Gung Memorial Hospital | — |
| Suspended | Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma NCT02156180 | Queensland Centre of Excellence for Head and Neck Cancer | — |